Intravenous recombinant tissue-type plasminogen activator in the extended time window and the US Food and Drug Administration: confused about the time.
Department of Neurology and the University of Pittsburgh Medical Center Stroke Institute, University of Pittsburgh Medical School,Pittsburgh, PA, USA. wechslerlr@upmc.edu
Lawrence R
LR
Wechsler
Tudor G
TG
Jovin
D002986:Clinical Trials as Topic; D057510:Endovascular Procedures; D005060:Europe; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D017408:Guidelines as Topic; D006801:Humans; D007275:Injections, Intravenous; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000188:drug therapy*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator